Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZALOX Study
2024-517237-40-00Phase 2Authorised
- Sponsor
- Heidelberg University
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of amsulostat and azacitidine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Heidelberg University. Planned start Jul 2025; status: authorised.
02
Drugs
amsulostatazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2024-517237-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517237-40-00.